High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases

Area of Science:

• Cardiovascular Research
• Lipid Metabolism
• Pharmacology

Background:

• Cardiovascular diseases (CVDs) pose a significant health burden, with statins being the primary treatment for lowering low-density lipoprotein (LDL) cholesterol.
• However, a substantial portion of patients do not fully benefit from statin therapy, highlighting the need for alternative treatments.
• The reverse cholesterol transport pathway, involving high-density lipoprotein (HDL), offers potential anti-atherogenic mechanisms.

Purpose of the Study:

• To review the therapeutic potential of HDL mimetics in managing atherosclerosis.
• To explore how HDL mimetics can optimize HDL function for cholesterol removal and anti-inflammatory effects.
• To evaluate specific HDL mimetics, such as apolipoprotein (Apo) A-I mimetic peptides, as novel anti-atherosclerotic agents.

Main Methods:

• Literature review of clinical trials, epidemiological studies, and preclinical research on HDL-targeted therapies.
• Analysis of the mechanisms of action for various HDL mimetics, including reconstituted HDL, ApoA-I Milano, and ApoA-I mimetic peptides.
• Focus on the Fukuoka University ApoA-I-mimetic peptide (FAMP) and its interaction with the ABCA1 transporter.

Main Results:

• HDL mimetics demonstrate significant atheroprotective potential in animal models.
• FAMP effectively facilitates cholesterol efflux via the ABCA1 transporter.
• FAMP enhances HDL's biological functions, acting as an anti-atherosclerotic agent without increasing HDL cholesterol levels.

Conclusions:

• HDL mimetics represent a promising therapeutic avenue for atherosclerotic diseases.
• Optimizing HDL function through mimetics can enhance cholesterol removal and mitigate inflammation.
• FAMP and similar agents offer a novel strategy for cardiovascular disease treatment, particularly for statin-resistant patients.